Biocon
Swapnil J. currently serves as the VP & Head of Corporate Strategy at Biocon Limited, where responsibilities include managing the CEO & MD’s office and overseeing investments in capacity expansion and cost improvement initiatives across various geographies. Prior experience includes leading the integration and commercial strategy for Dr. Reddy's Consumer Health in Europe, where management of significant acquisitions was central to the role. Swapnil also held director-level positions focused on strategic initiatives, marketing excellence, and new product portfolio strategy at Dr. Reddy’s Laboratories, alongside consultancy roles at Decision Resources Group and IQVIA. Educational qualifications include a B.Tech in Civil Engineering from the Indian Institute of Technology, Bombay.
This person is not in any teams
This person is not in any offices
Biocon
21 followers
Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from Lab to Market. The Company's brands include INSUGEN (rh-insulin), BASALOG (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab) and ALZUMAb (Itolizumab), an anti-CD6 monoclonal antibody. It has a pipeline of Biosimilars and Novel Biologics at various stages of development, including Insulin Tregopil, an oral insulin analog.